- Home
- DYAI vs KYNB Comparison
DYAI vs KYNB Comparison
Compare DYAI & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYAI | KYNB |
|---|---|---|
| Founded | 1979 | 1993 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 27.1M |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | DYAI | KYNB |
|---|---|---|
| Price | $1.00 | $7.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 220.4K | 7.0K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,090,345.00 | N/A |
| Revenue This Year | $122.79 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $6.32 |
| 52 Week High | $1.60 | $9.58 |
Technical Indicators
Market Signals| Indicator | DYAI | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 47.70 |
| Support Level | $0.76 | $6.66 |
| Resistance Level | $1.21 | $7.37 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 10.77 | 44.07 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.